Pregabalin litigation - why did the SPCs lapse?

No items found.
​
31 May 2018
Tags
Life
Table of contents
  • Toc Heading
  • Toc Heading

Writing in the GRUR Newsletter ahead of the decision of the Supreme Court on the validity of a European patent owned by a subsidiary of Pfizer, covering the use of pregabalin in the treatment of pain, Darren Smyth looks at the various theories as to why the related SPCs were allowed to lapse.

Related articles

See all articles

EIP recognised across the board in IAM Patent 1000, 2026
29 May 2026
We're pleased to be featured again in the IAM Patent 1000, 2026. The guide is one of the most trusted independent rankings of patent professionals worldwide, built on months of research and direct feedback from clients and peers.
​
Five EIP leaders recognised in WIPR 2026
11 May 2026
We are delighted to announce that five members of our team have been named in WIPR Leaders 2026: Jerome Spaargaren, Heather McCann, Gary Moss, Andrew Sharples, and Sebastian Fuchs.
​
EIP recognsied for strategic leadership in patent law at the Professional Services Management Excellence Awards
26 March 2026
EIP has been recognised with two Professional Services Management Excellence Awards 2026, including Excellence in Strategic Leadership and Best in Theme: Leadership. The awards reflect the firm’s commitment to aligning patent expertise with commercial insight, strengthening leadership across the firm and delivering patent strategy that supports investment, growth and high‑value business decisions.
​